Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | ABL2 | P42684 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811600 | 0.89 | GPR119 (0.51) | MEN1KMT2AJAK2JAK3PTK2 | |
| SCHEMBL2811603 | 0.89 | GPR119 (0.51) | MEN1KMT2AJAK2JAK3PTK2 | |
| SCHEMBL528039 | 0.88 | MEN1 (0.48) | MEN1KMT2AALDH1A1ABL1EGFR | |
| SCHEMBL1752278 | 0.87 | PDE4B (0.53) | MEN1KMT2AALDH1A1ABL1EGFR | |
| SCHEMBL19168895 | 0.87 | MEN1 (0.48) | MEN1KMT2AALDH1A1ABL1EGFR | |
| SCHEMBL12592451 | 0.87 | PDE4B (0.53) | MEN1KMT2AALDH1A1ABL1EGFR | |
| SCHEMBL14256143 | 0.86 | JAK2 (0.46) | MEN1KMT2AJAK2JAK3PTK2 | |
| SCHEMBL7841659 | 0.86 | GPR119 (0.56) | MEN1KMT2AJAK2JAK3PTK2 | |
| SCHEMBL7842833 | 0.86 | GPR119 (0.56) | MEN1KMT2AJAK2JAK3PTK2 | |
| SCHEMBL7841657 | 0.86 | GPR119 (0.56) | MEN1KMT2AJAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-12-01 | — | — | US | disclosed |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-12-01 | — | — | US | disclosed |
| US-9440984-B2 | Pyrrolotriazines as ALK inhibitors | CEPHALON, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440984-B2 | Pyrrolotriazines as ALK inhibitors | CEPHALON, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440984-B2 | Pyrrolotriazines as ALK inhibitors | CEPHALON, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| EP-3004111-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | Cephalon, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160068535-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068535-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160068535-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. | 2016-03-10 | — | — | US | disclosed |
| WO-2014193932-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
| WO-2014193932-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | CEPHALON, INC. (US) | 2014-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068535-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | ALK, ACVR1, AGTR1 | MEN1 3460/4885KMT2A 468/4885JAK2 82/4885 |
| US-20160347756-A1 | PYRROLOTRIAZINES AS ALK INHIBITORS | ALK, ACVR1, AGTR1 | MEN1 3460/4885KMT2A 468/4885JAK2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.